Open AccessResearch and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
Author(s) -
Vinay Prasad,
Sham Mailankody
Publication year - 2017
Publication title -
jama internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.14
H-Index - 342
eISSN - 2168-6114
pISSN - 2168-6106
DOI - 10.1001/jamainternmed.2017.3601
Subject(s) - medicine , cancer drugs , revenue , drug development , drug , transparency (behavior) , food and drug administration , earnings , finance , pharmacology , law , business , political science
A common justification for high cancer drug prices is the sizable research and development (R&D) outlay necessary to bring a drug to the US market. A recent estimate of R&D spending is $2.7 billion (2017 US dollars). However, this analysis lacks transparency and independent replication.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom